✦ LIBER ✦

Design and Rationale of the LAPLACE-TIMI 57 Trial: A Phase II, Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy

✍ Scribed by Payal Kohli; Nihar R. Desai; Robert P. Giugliano; Jae B. Kim; Ransi Somaratne; Fannie Huang; Beat Knusel; Shannon McDonald; Timothy Abrahamsen; Scott M. Wasserman; Robert Scott; Marc S. Sabatine

Book ID: 112061522
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 123 KB
Volume: 35
Category: Article
ISSN: 0160-9289
DOI: 10.1002/clc.22014

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy, safety, and tolerability of a

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

✍ Robert P Giugliano; Nihar R Desai; Payal Kohli; William J Rogers; Ransi Somaratn 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 353 KB

A phase II, double-blind, randomized, pl

A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): rationale and design

✍ Michael Zile; William Gaasch; William Little; Gary Francis; Luigi Tavazzi; John 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 108 KB

Efficacy, safety, and tolerability of a

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

✍ Michael J Koren; Rob Scott; Jae B Kim; Beat Knusel; Thomas Liu; Lei Lei; Michael 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 384 KB

Rationale and design of the Anti-Xa Ther

Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome

✍ C. Michael Gibson; Jessica L. Mega; Paul Burton; Shinya Goto; Freek Verheugt; Ch 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 428 KB

A phase II, randomized, double-blind, pl

A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis

✍ Michael Yellin; Igor Paliienko; Andra Balanescu; Semen Ter-Vartanian; Vira Tselu 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB

Rationale and design of the EMBRACE STEM

Rationale and design of the EMBRACE STEMI Study: A phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction

✍ Chakrabarti, Anjan K.; Feeney, Kristin; Abueg, Cassandra; Brown, David A.; Czyz, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 322 KB